TIDMVER
RNS Number : 9220Z
Vernalis PLC
06 September 2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
FOR IMMEDIATE RELEASE
6 September 2018
RECOMMED CASH OFFER
for
VERNALIS PLC
by
LIGAND HOLDINGS UK LTD.
(a wholly owned subsidiary of Ligand Pharmaceuticals
Incorporated)
to be effected
by means of a scheme of arrangement of Vernalis plc
under Part 26 of the Companies Act 2006
Publication and Posting of Scheme Document
On 9 August 2018, the boards of Vernalis plc ("Vernalis") and
Ligand Holdings UK Ltd ("Ligand UK") announced that they had agreed
the terms of a recommended cash offer pursuant to which Ligand UK
will acquire the entire issued and to be issued share capital of
Vernalis (the "Acquisition"), which will be effected by means of a
Court sanctioned scheme of arrangement under Part 26 of the
Companies Act 2006 ("Scheme").
The Board of Vernalis is pleased to announce that a scheme
document relating to the Acquisition (the "Scheme Document"),
together with associated Forms of Proxy, are today being published
and posted to Vernalis Shareholders. The Scheme Document contains,
inter alia, a letter from the Chairman of Vernalis, the full terms
and conditions of the Scheme, an explanatory statement pursuant to
section 897 of the Companies Act 2006, notices of the Court Meeting
and General Meeting, the expected timetable of principal events and
details of the actions to be taken by Vernalis Shareholders.
Vernalis is also sending the Scheme Document to participants in the
Vernalis Share Schemes for information only and those persons with
information rights.
Capitalised terms in this announcement (the "Announcement"),
unless otherwise defined, have the same meanings as set out in the
Scheme Document. Copies of this Announcement and the Scheme
Document will be available free of charge (subject to certain
restrictions relating to persons in Restricted Jurisdictions) on
Vernalis' website at www.vernalis.com and on the Ligand Group's
website at www.investor.ligand.com/vernalisoffer up to and
including the Effective Date. The contents of these websites are
not incorporated into, and do not form part of, this
Announcement.
Notices of the Court Meeting and General Meeting
As detailed further in the Scheme Document, the Scheme is
subject to the Conditions. To become effective, the Scheme
requires, among other things, that the requisite majorities of
Scheme Shareholders vote in favour of the Scheme at the Court
Meeting and that the requisite majorities of Vernalis Shareholders
vote in favour of the special resolution to be proposed at the
General Meeting.
Notices convening the Court Meeting and the General Meeting,
each of which will be held at the offices of Covington &
Burling LLP, 265 Strand, London WC2R 1BH on 2 October 2018, are set
out in the Scheme Document. The Court Meeting will start at 11.00
a.m. and the General Meeting will start at 11.15 a.m. (or as soon
thereafter as the Court Meeting has been concluded or adjourned).
Forms of Proxy for use at such Meetings are enclosed with the
Scheme Document.
It is important that, for the Court Meeting, as many votes as
possible are cast so that the Court may be satisfied that there is
a fair and reasonable representation of the opinion of Scheme
Shareholders. Scheme Shareholders are therefore strongly encouraged
to complete, sign and return their Forms of Proxy (once received)
(or appoint a proxy through the CREST electronic proxy appointment
service) as soon as possible and in any event in accordance with
the instructions for doing so by the deadlines referred to in the
timetable below.
Cancellation of admission of Vernalis Shares to trading on
AIM
If the Scheme becomes effective in accordance with its terms, it
is intended that dealings in Vernalis Shares will be suspended at
7.30 a.m. on 9 October 2018 and subsequently Vernalis Shares will
be cancelled from admission to trading on AIM at 7.00 a.m. on 10
October 2018.
Timetable
The current expected timetable of principal events for the
implementation of the Scheme is set out below and in the Scheme
Document. If any of the key dates set out in the expected timetable
changes, an announcement will be made through a Regulatory
Information Service.
All times shown in this Announcement are references to London
time unless otherwise stated.
EXPECTED TIMETABLE OF PRINCIPAL EVENTS
The following indicative timetable sets out expected dates for
the implementation of the Scheme.
Event Time and/or date
Latest time for lodging Forms of Proxy and registering proxy
appointments through CREST for the:
Court Meeting (blue
form)...........................................................
11.00 a.m. on 28 September 2018(1)
General Meeting (yellow
form).................................................... 11.15
a.m. on 28 September 2018(2)
Voting Record Time for the Court Meeting and the
General
Meeting................................................................
close of business on 28 September 2018(3)
Court
Meeting....................................................................................
11.00 a.m. on 2 October 2018
General
Meeting..............................................................................
11.15 a.m. on 2 October 2018(4)
The following dates are indicative only and are subject to
change(5)
Court
Hearing............................................................................................................
8 October 2018
Last day of dealings in, and for registration of transfers of,
and for
disablement in CREST of, Vernalis
Shares................................................ 6.00 p.m. on
8 October 2018
Scheme Record
Time...............................................................................
6.00 p.m. on 8 October 2018
Dealings in Vernalis Shares
suspended......................................................
7.30 a.m. on 9 October 2018
Expected Effective Date of the
Scheme.......................................................................
9 October 2018
Cancellation of admission to trading of Vernalis Shares on
AIM................ 7.00 a.m. on 10 October 2018
Despatch of cheques and crediting of CREST for Cash
Consideration due
under the
Scheme................................................................................................
By 23 October 2018
Long Stop
Date...................................................................................................
31 December 2018(6)
Notes:
1. It is requested that blue Forms of Proxy for the Court
Meeting be lodged not later than 48 hours before the time appointed
for the Court Meeting, excluding any part of a day that is not a
business day. Blue Forms of Proxy not so lodged may be handed to
the Chairman of the Court Meeting or Link Asset Services on behalf
of the Chairman of the Court Meeting before the start of the Court
Meeting.
2. Yellow Forms of Proxy for the General Meeting must be lodged
not later than 48 hours before the time appointed for the General
Meeting, excluding any part of a day that is not a business day.
Yellow Forms of Proxy for the General Meeting not lodged by this
time will be invalid.
3. If either the Court Meeting or the General Meeting is
adjourned, the Voting Record Time for the relevant adjourned
meeting will be close of business on the day which is two days
before the date of the adjourned meeting, excluding any part of a
day that is not a business day.
4. Or as soon as the Court Meeting shall have concluded or been adjourned.
5. These dates are indicative only and will depend, among other things, on the date upon which:
(i) the Conditions are satisfied or (if capable of waiver) waived;
(ii) the Court sanctions the Scheme; and
(iii) the Court Order is delivered to the Registrar of
Companies.
6. This is the latest date by which the Scheme may become
effective unless Ligand UK and Vernalis agree (and the Panel and,
if required, the Court permit) a later date.
All references in this document to times are to London time
unless otherwise stated. The dates and times given are indicative
only and are based on Vernalis' current expectations and may be
subject to change (including as a result of changes to the
regulatory timetable). If any of the expected times and/or dates
above change, the revised times and/or dates will be notified to
Vernalis Shareholders by announcement through a Regulatory
Information Service with such announcement being made available on
the Ligand Group's website at www.investor.ligand.com/vernalisoffer
and on Vernalis' website at www.vernalis.com. Vernalis ADS Holders
and overseas Vernalis Shareholders should refer to Part Six of the
Scheme Document, which contains important information relevant to
such holders.
Enquiries
Vernalis plc
Ian Garland, Chief Executive Officer
David Mackney, Chief Financial Officer +44 (0) 118 938 0015
Canaccord Genuity Limited (Nominated Adviser
and broker to Vernalis)
Henry Fitzgerald-O'Connor
Emma Gabriel +44 (0) 20 7523 8000
Evercore (Financial adviser to Vernalis)
Julian Oakley
Alan Beirne +44 (0) 20 7653 6000
Ligand Pharmaceuticals Incorporated
Matthew Korenberg
Todd Pettingill +1 858 550 7500
finnCap Ltd (Financial adviser to Ligand
UK)
Henrik Persson
Giles Rolls
Max Bullen-Smith +44 (0) 20 7220 0500
MTS Securities, LLC (Financial adviser
to Ligand UK)
Mark Menkowski +1 212 887 2100
Important notices relating to financial advisers
Evercore, which is authorised and regulated by the Financial
Conduct Authority in the United Kingdom, is acting solely for
Vernalis as financial adviser in relation to the matters referred
to in this announcement and for no one else. Evercore will not be
responsible to anyone other than Vernalis for providing the
protections afforded to its clients or for providing advice in
relation to the contents of this announcement or any arrangement
referred to herein. Neither Evercore, nor any of its affiliates,
owes or accepts any duty, liability or responsibility whatsoever
(whether direct or indirect, whether in contract, in tort, under
statue or otherwise) to any person other than Vernalis in
connection with this announcement, any statement contained herein
or otherwise. Evercore has given, and not withdrawn, its consent to
the inclusion in this announcement of the references to its name
and the advice it has given to Vernalis in the form and context in
which they appear.
Canaccord Genuity, which is authorised and regulated by the
Financial Conduct Authority in the United Kingdom, is acting solely
for Vernalis as Nominated Adviser and broker in relation to the
matters referred to in this announcement and for no one else.
Canaccord Genuity will not be responsible to anyone other than
Vernalis for providing the protections afforded to its clients or
for providing advice in relation to the contents of this
announcement or any arrangement referred to herein. Neither
Canaccord Genuity, nor any of its affiliates, owes or accepts any
duty, liability or responsibility whatsoever (whether direct or
indirect, whether in contract, in tort, under statue or otherwise)
to any person other than Vernalis in connection with this
announcement, any statement contained herein or otherwise.
Canaccord Genuity has given, and not withdrawn, its consent to the
inclusion in this announcement of the references to its name in the
form and context in which they appear.
finnCap, which is authorised and regulated by the Financial
Conduct Authority in the United Kingdom, is acting exclusively as
financial adviser to Ligand UK and for no one else in connection
with the matters referred to in this announcement and will not be
responsible to anyone other than Ligand UK for providing the
protections afforded to its clients or for providing advice in
relation to the matters referred to in this announcement. Neither
finnCap, nor any of its affiliates, owes or accepts any duty,
liability or responsibility whatsoever (whether direct or indirect,
whether in contract, in tort, under statute or otherwise) to any
person who is not a client of finnCap in connection with this
announcement, any statement contained herein or otherwise. finnCap
has given, and not withdrawn, its consent to the inclusion in this
announcement of the references to its name in the form and context
in which they appear.
MTS is acting exclusively as financial adviser to Ligand UK and
for no one else in connection with the matters referred to in this
announcement and will not be responsible to anyone other than
Ligand UK for providing the protections afforded to its clients or
for providing advice in relation to the matters referred to in this
announcement. MTS is a US registered broker dealer and is not
advising Ligand UK for the purposes of the Code. Neither MTS, nor
any of its affiliates, owes or accepts any duty, liability or
responsibility whatsoever (whether direct or indirect, whether in
contract, in tort, under statute or otherwise) to any person who is
not a client of MTS in connection with this announcement, any
statement contained herein or otherwise.
Further information
This announcement is for information purposes only and is not
intended to, and does not, constitute or form part of any offer,
invitation or the solicitation of an offer to purchase, otherwise
acquire, subscribe for, sell or otherwise dispose of any
securities, or the solicitation of any vote or approval in any
jurisdiction in contravention of applicable law. The Acquisition is
being made solely pursuant to the terms of the Scheme Document
which contains the full terms and conditions of the Acquisition,
including details of how to vote at the Meetings in respect of the
Acquisition. Any vote in relation to the Acquisition should be made
only on the basis of the information contained in the Scheme
Document. Vernalis Shareholders are strongly advised to read the
Scheme Document carefully.
The statements contained in this Announcement are made as at the
date of this Announcement, unless some other time is specified in
relation to them.
This Announcement does not constitute a prospectus or prospectus
equivalent document.
Overseas jurisdictions
The release, publication or distribution of this announcement in
or into jurisdictions other than the United Kingdom may be
restricted by law and therefore any persons who are subject to the
laws of any jurisdiction other than the United Kingdom should
inform themselves about, and observe, any applicable legal or
regulatory requirements. In particular, the ability of persons who
are not resident in the United Kingdom or who are subject to the
laws of another jurisdiction to vote their Vernalis Shares with
respect to the Scheme at the Court Meeting or the General Meeting,
or to execute and deliver Forms of Proxy appointing another person
to vote at the Court Meeting or the General Meeting on their
behalf, may be affected by the laws of the relevant jurisdictions
in which they are located or to which they are subject. Any failure
to comply with the applicable legal or regulatory restrictions of
any jurisdiction may constitute a violation of the securities laws
of any such jurisdiction. To the fullest extent permitted by
applicable law, the companies and persons involved in the
Acquisition disclaim any responsibility or liability for the
violation of such restrictions by any person. This announcement has
been prepared for the purpose of complying with English law, the
rules of the London Stock Exchange, the AIM Rules and the Code and
the information disclosed may not be the same as that which would
have been disclosed if this announcement had been prepared in
accordance with the laws of jurisdictions outside of the United
Kingdom.
Unless otherwise determined by Ligand UK or required by the
Code, and permitted by applicable law and regulation, the
Acquisition will not be made available, directly or indirectly, in,
into or from a Restricted Jurisdiction or any jurisdiction where to
do so would violate the laws in that jurisdiction and no person may
vote in favour of the Acquisition by any such use, means,
instrumentality or from within a Restricted Jurisdiction or any
other jurisdiction if to do so would constitute a violation of the
laws of that jurisdiction. Accordingly, copies of this announcement
and any formal documentation relating to the Acquisition are not
being, and must not be, directly or indirectly, mailed, transmitted
or otherwise forwarded, distributed or sent in or into or from any
Restricted Jurisdiction or any other jurisdiction where to do so
would constitute a violation of the laws of that jurisdiction, and
persons receiving such documents (including custodians, nominees
and trustees) must not mail or otherwise forward, distribute or
send such documents in or into or from any Restricted Jurisdiction.
Doing so may render invalid any related purported vote in respect
of the Acquisition. If the Acquisition is implemented by way of a
Takeover Offer (unless otherwise permitted by applicable law and
regulation), the Takeover Offer may not be made directly or
indirectly, in or into, or by the use of mails or any means or
instrumentality (including, but not limited to, facsimile, e-mail
or other electronic transmission or telephone) of interstate or
foreign commerce of, or of any facility of a national, state or
other securities exchange of any Restricted Jurisdiction and the
Takeover Offer may not be capable of acceptance by any such use,
means, instrumentality or facilities or from within any Restricted
Jurisdiction.
Further details in relation to Vernalis Shareholders in overseas
jurisdictions is contained in the Scheme Document.
Notice to US holders of Vernalis Shares and Vernalis ADSs
The Acquisition relates to the shares of an English company and
is being made by means of a scheme of arrangement provided for
under English company law. A transaction effected by means of a
scheme of arrangement is not subject to the tender offer rules or
the proxy solicitation rules under the US Exchange Act.
Accordingly, the Acquisition is subject to the disclosure
requirements and practices applicable in the United Kingdom to
schemes of arrangement which differ from the disclosure
requirements of United States tender offer and proxy solicitation
rules. If, in the future, Ligand UK exercises the right to
implement the Acquisition by way of a Takeover Offer and determines
to extend such Takeover Offer into the United States, the
Acquisition will be made pursuant to applicable UK tender offer
rules and securities laws and otherwise in accordance with the
requirements of the Code. Accordingly, any such Takeover Offer will
be subject to disclosure and other procedural requirements,
including with respect to withdrawal rights, offer timetable,
settlement procedures and timing of payments, that are different
from those applicable to tender offers made in accordance with US
procedures and law. Financial information included in this
announcement and the Scheme Document has been or will be prepared
in accordance with accounting standards applicable in the United
Kingdom that may not be comparable to financial information of US
companies or companies whose financial statements are prepared in
accordance with generally accepted accounting principles in the
United States.
It may be difficult for US holders of Vernalis Shares (and
Vernalis ADS Holders) to enforce their rights and any claim arising
out of the US federal securities laws, since Vernalis is located in
a non-US jurisdiction, and some or all of their officers and
directors may be residents of a non-US jurisdiction. US holders of
Vernalis Shares and Vernalis ADS Holders may not be able to sue a
non-US company or its officers or directors in a non-US court for
violations of the US securities laws. Further, it may be difficult
to compel a non-US company and its affiliates to subject themselves
to a US court's judgement.
Neither the SEC nor any securities commission of any state of
the United States has approved or disapproved the Acquisition,
passed upon the fairness of the Acquisition or passed upon the
adequacy or accuracy of this announcement. Any representation to
the contrary is a criminal offence in the United States.
In accordance with normal UK practice and pursuant to Rule
14e-5(b) of the US Exchange Act, Ligand UK or its nominees or
brokers (acting as agents) may from time to time make certain
purchases of, or arrangements to purchase, Vernalis Shares outside
the United States, other than pursuant to the Acquisition, until
the date on which the Scheme and/or Takeover Offer becomes
effective, lapses or is otherwise withdrawn. These purchases may
occur either in the open market at prevailing prices or in private
transactions at negotiated prices. Any information about such
purchases will be disclosed as required in the UK, will be reported
to the Regulatory News Service of the London Stock Exchange and
will be available on the London Stock Exchange website.
Forward-looking statements
This announcement may contain statements about the Ligand Group
and the Vernalis Group which are, or may be deemed to be,
"forward-looking statements" and which are prospective in nature.
All statements other than statements of historical fact included in
this announcement may be forward-looking statements. They are based
on current expectations and projections about future events, and
are therefore subject to risks and uncertainties which could cause
actual results to differ materially from the future results
expressed or implied by the forward-looking statements. Often, but
not always, forward-looking statements can be identified by the use
of forward-looking words such as "plans", "expects", "is expected",
"is subject to", "budget", "scheduled", "estimates", "forecasts",
"predicts", "intends", "anticipates", "believes", "targets",
"aims", "projects", "future-proofing" or words or terms of similar
substance or the negative of such words or terms, as well as
variations of such words and phrases or statements that certain
actions, events or results "may", "could", "should", "would",
"might" or "will" be taken, occur or be achieved. Such statements
are qualified in their entirety by the inherent risks and
uncertainties surrounding future expectations. Forward-looking
statements may include statements relating to the following: (i)
future capital expenditures, expenses, revenues, earnings,
synergies, economic performance, indebtedness, financial condition,
dividend policy, losses and future prospects; (ii) business and
management strategies and the expansion and growth of the Ligand
Group's or the Vernalis Group's operations and potential synergies
resulting from the Acquisition; and (iii) the effects of global
economic conditions and governmental regulation on the Ligand
Group's or the Vernalis Group's business.
Such forward-looking statements involve known and unknown risks
and uncertainties that could significantly affect expected results
and are based on certain key assumptions. Many factors may cause
the actual results, performance or achievements of the Ligand Group
or the Vernalis Group to be materially different from any future
results, performance or achievements expressed or implied by the
forward-looking statements. These factors include changes in the
global, political, economic, business, competitive, market and
regulatory forces, future exchange and interest rates, changes in
tax rates and future business combinations or disposals. For a
discussion of important factors which could cause actual results to
differ from forward-looking statements in relation to the Ligand
Group or the Vernalis Group, refer to the results of the Ligand
Group for the financial year ended 31 December 2017 and of the
Vernalis Group for the financial year ended 30 June 2017,
respectively. Each of the Ligand Group and the Vernalis Group, and
each of their respective members, directors, officers, employees,
advisers and persons acting on their behalf, expressly disclaims
any intention or obligation to update or revise any forward-looking
or other statements contained in this announcement, whether as a
result of new information, future events or otherwise, except as
required by applicable law.
No member of the Ligand Group, nor the Vernalis Group, nor any
of their respective associates, directors, officers, employees or
advisers, provides any representation, assurance or guarantee that
the occurrence of the events expressed or implied in any
forward-looking statements in this announcement will actually
occur.
Except as expressly provided in this announcement, no
forward-looking or other statements have been reviewed by the
auditors of the Ligand Group or the Vernalis Group. All subsequent
oral or written forward-looking statements attributable to any
member of the Ligand Group or Vernalis Group, or any of their
respective associates, directors, officers, employees or advisers,
are expressly qualified in their entirety by the cautionary
statement above.
No profit forecast and profit estimate
No statement in this announcement is intended as a profit
forecast or estimate for any period and no statement in this
announcement should be interpreted to mean that earnings or
earnings per share for Vernalis for the current or future financial
years would necessarily match or exceed the historical published
earnings or earnings per share for Vernalis.
Disclosure requirements of the Code
Under Rule 8.3(a) of the Code, any person who is interested in 1
per cent. or more of any class of relevant securities of an offeree
company or of any securities exchange offeror (being any offeror
other than an offeror in respect of which it has been announced
that its offer is, or is likely to be, solely in cash) must make an
Opening Position Disclosure following the commencement of the offer
period and, if later, following the announcement in which any
securities exchange offeror is first identified. An Opening
Position Disclosure must contain details of the person's interests
and short positions in, and rights to subscribe for, any relevant
securities of each of (i) the offeree company and (ii) any
securities exchange offeror(s). An Opening Position Disclosure by a
person to whom Rule 8.3(a) of the Code applies must be made by no
later than 3.30 pm (London time) on the 10th business day following
the commencement of the Offer Period and, if appropriate, by no
later than 3.30 pm (London time) on the 10th business day following
the announcement in which any securities exchange offeror is first
identified. Relevant persons who deal in the relevant securities of
the offeree company or of a securities exchange offeror prior to
the deadline for making an Opening Position Disclosure must instead
make a Dealing Disclosure.
Under Rule 8.3(b) of the Code, any person who is, or becomes,
interested in 1 per cent. or more of any class of relevant
securities of the offeree company or of any securities exchange
offeror must make a Dealing Disclosure if the person deals in any
relevant securities of the offeree company or of any securities
exchange offeror. A Dealing Disclosure must contain details of the
dealing concerned and of the person's interests and short positions
in, and rights to subscribe for, any relevant securities of each of
(i) the offeree company and (ii) any securities exchange offeror,
save to the extent that these details have previously been
disclosed under Rule 8 of the Code. A Dealing Disclosure by a
person to whom Rule 8.3(b) of the Code applies must be made by no
later than 3.30 pm (London time) on the business day following the
date of the relevant dealing.
If two or more persons act together pursuant to an agreement or
understanding, whether formal or informal, to acquire or control an
interest in relevant securities of an offeree company or a
securities exchange offeror, they will be deemed to be a single
person for the purpose of Rule 8.3 of the Code.
Opening Position Disclosures must also be made by the offeree
company and by any offeror and Dealing Disclosures must also be
made by the offeree company, by any offeror and by any persons
acting in concert with any of them (see Rules 8.1, 8.2 and 8.4 of
the Code).
Details of the offeree and offeror companies in respect of whose
relevant securities Opening Position Disclosures and Dealing
Disclosures must be made can be found in the Disclosure Table on
the Panel's website at www.thetakeoverpanel.org.uk, including
details of the number of relevant securities in issue, when the
offer period commenced and when any offeror was first identified.
You should contact the Panel's Market Surveillance Unit on +44
(0)20 7638 0129 if you are in any doubt as to whether you are
required to make an Opening Position Disclosure or a Dealing
Disclosure.
Information relating to Vernalis Shareholders
Please be aware that addresses, electronic addresses and certain
other information provided by Vernalis Shareholders and Vernalis
ADS Holders, persons with information rights and other relevant
persons for the receipt of communications from Vernalis may be
provided to Ligand UK during the Offer Period as required under
Section 4 of Appendix 4 to the Code to comply with Rule 2.11(c) of
the Code.
Publication on website
Pursuant to rule 26 of the Code, a copy of this announcement
will be available, subject to certain restrictions relating to
persons resident in, or subject to the laws and/or regulations, of
Restricted Jurisdictions, for inspection on the Ligand Group's
website at www.investor.ligand.com/vernalisoffer and on Vernalis'
website at www.vernalis.com promptly and in any event by no later
than 12 noon (London time) on the business day following the date
of this announcement. For the avoidance of doubt the contents of
those websites are not incorporated into, and do not form part of,
this announcement.
Vernalis Shareholders may request a hard copy of this
announcement, free of charge, by contacting Vernalis on +44 (0) 118
938 0015. Vernalis Shareholders may also request that all future
documents, announcements and information to be sent to them in
relation to the Acquisition should be provided in hard copy
form.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFFIALIEIIT
(END) Dow Jones Newswires
September 06, 2018 02:01 ET (06:01 GMT)
Vernalis (LSE:VER)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vernalis (LSE:VER)
Historical Stock Chart
From Oct 2023 to Oct 2024